Ro 106-9920 is an inhibitor of NF-κB activation, possibly via selective inhibition of LPS- and TNF-α-induced IκBα ubiquitination (IC50 = 3 μM). Ro 106-9920 blocks subsequent production of TNF-α, IL-1β and IL-6. Inhibits mucin production in an in vitro model of COPD, and is anti-inflammatory following oral administration in vivo. Also weakly inhibits EGFR, 5-lipoxygenase and iNOS.
ChEBI: 6-(benzenesulfinyl)tetrazolo[1,5-b]pyridazine is a sulfoxide.
Inhibitor of NF- κ B activation, possibly via selective inhibition of LPS- and TNF- α -induced I κ B α ubiquitination (IC 50 = 3 μ M). Blocks subsequent production of TNF- α , IL-1 β and IL-6. Inhibits mucin production in an in vitro model of COPD, and is anti-inflammatory following oral administration in vivo . Also weakly inhibits EGFR, 5-lipoxygenase and iNOS.
